Osteoporosis in 10 years time: a glimpse into the future of osteoporosis
- PMID: 35342458
- PMCID: PMC8941690
- DOI: 10.1177/1759720X221083541
Osteoporosis in 10 years time: a glimpse into the future of osteoporosis
Abstract
Patients living with osteoporosis are projected to increase dramatically in the next decade. Alongside the forecasted increased societal and economic burden, we will live a crisis of fractures. However, we will have novel pharmacological treatment to face this crisis and, more importantly, new optimized treatment strategies. Fracture liaison services will be probably implemented on a large scale worldwide, helping to prevent additional fractures in high-risk patients. In the next decade, novel advances in the diagnostic tools will be largely available. Moreover, new and more precise fracture risk assessment tools will change our ability to detect patients at high risk of fractures. Finally, big data and artificial intelligence will help us to move forward into the world of precision medicine. In the present review, we will discuss the future epidemiology and costs of osteoporosis, the advances in early and accurate diagnosis of osteoporosis, with a special focus on biomarkers and imaging tools. Then we will examine new and refined fracture risk assessment tools, the role of fracture liaison services, and a future perspective on osteoporosis treatment.
Keywords: bone mineral density; fractures; future perspective; osteoporosis.
© The Author(s), 2022.
Conflict of interest statement
Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: G.A. reports personal fees from Theramex and Galapagos outside the submitted work. A.F. reports personal fees from Abiogen, Novartis, and Neopharmed, outside the submitted work. D.G. has received advisory board honoraria, consultancy fees, and/or speaker fees from Abiogen, Celgene, Eli-Lilly, Neopharmed-Gentili, Pfizer, and UCB. M.I.D. reports research grants from Pfizer and Horizon. K.G.S. reports research grants from Amgen, Mereo, and Radius and has received consultancy fees from Amgen, outside the submitted work. O.V. has received advisory board honoraria and speaker fees from Gilead, Fresenius Kabi, Biogen, Ely-Lilly, UCB, AbbVie, MSD, and BMS. M.R. reports advisory board honoraria, consultancy fees, and/or speaker fees from AbbVie, Abiogen, Amgen, BMS, Eli-Lilly, Galapagos, Theramex, and UCB, outside the submitted work.
References
-
- Burge R, Dawson-Hughes B, Solomon DH, et al.. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22: 465–475. - PubMed
-
- Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726–1733. - PubMed
LinkOut - more resources
Full Text Sources